Home » Newsletters » BioWorld Science

BioWorld Science

June 7, 2010

View Archived Issues

Sipuleucel-T is safe and well tolerated in CRPC and ADPC

CF-101 displays safety and potent anti-inflammatory activity

Eprosartan/bisoprolol shows efficacy in chronic heart failure and pulmonary hypertension

Lucinactant protects against IRI in experimental lung transplantation

Spermine identified as putative biomarker of stroke diagnosis and severity

Hedgehog signaling inhibitors claimed by Lilly for cancer therapy

Evotec presents new histamine H3 receptor antagonists

Biotie Therapies and Wyeth claim new PDE inhibitors

Boehringer Ingelheim identifies new collagenase 3 inhibitors

Abbott discloses highlights of first quarter 2010

Raptor licenses intellectual property related to treatment of Huntington's disease

FDA advisory committee reviews MedImmune's motavizumab BLA

FDA advisory committee review of lorcaserin set for September

Astellas announces second tender offer period for OSI share acquisition

FDA approves Roche Diagnostics' Elecsys anti-HCV assay

Aoxing and PPL to codevelop new pain and addiction therapies

Intercell partners with Inclinix for phase III trial of travelers' diarrhea vaccine

FDA grants orphan drug status to telatinib for gastric cancer

YM raises funds for phase II part of CYT-387 trial in myelofibrosis

CSL Behring's Berinert approved in Canada for HAE

Cephalon discontinues development of Nuvigil in schizophrenia

Phase II trial of Ocuseva in retinitis pigmentosa completed

Nabriva begins phase II BC-3781 trial in skin and skin structure infections

Tioga begins phase III asimadoline trial in irritable bowel syndrome

Phase I data presented on HuM195/rGel in advanced myeloid malignancies

CT-322 is active in phase II trial in recurrent glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...